RecruitingType 2 Diabetes
SGLT2i, Pioglitazone, and Ketone Production in T2D
Eligible age
30–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
Sponsor: The University of Texas Health Science Center at San Antonio
You may qualify if…
- ✓ Ages 30-75 years
- ✓ Body Mass Index (BMI) 21-45 kg/m2
- ✓ Hemoglobin A1C (HbA1c) = 7.0-11%
- ✓ Estimated glomerular filtration rate (eGFR) \> 60 ml/min/1.73m2
- ✓ Blood Pressure (BP) \< 145/85 mmHg
- ✓ Participants must be in general good health based on medical history, physical exam, screening blood chemistries, complete blood chemistry (CBC), thyroid stimulating hormone/thyroxine (TSH/T4), electrocardiogram (EKG), and urinalysis
- ✓ Stable body weight (±1.5 kg) over the last 3 months and must not participate in an excessively heavy exercise program
- ✓ Patients treated with diet, sulfonylurea (SU), metformin (MET), or SU/MET
You may not qualify if…
- ✕ Patients treated with Glucagon-like peptide 1 receptor agonists (GLP-1 RA), Dipeptidyl Peptidase IV inhibitors (DPP-4i), Thiazolidinediones (TZD), or insulin are excluded
- ✕ Patients taking medications (other than SU/MET) known to affect glucose metabolism are excluded
- ✕ Subjects with evidence of proliferative retinopathy or eGFR \< 60 are excluded
- ✕ Women of childbearing potential are excluded unless they are taking/using appropriate contractive medications/devices
Where it's recruiting
Texas
San Antonio
Source: ClinicalTrials.gov · NCT07053319 · last updated 2026-05-12